What kind of medicine is sparsentan/sparsentan? What diseases is it suitable for?

Sparsentan is a dual-action drug that combines the action mechanisms of endothelin receptor antagonist and angiotensin II receptor antagonist. It is mainly used to treat primary immunoglobulin A nephropathy (IgAN) . This is an immune-mediated kidney disease, mainly characterized by immune deposition in the renal tubules and glomeruli, leading to gradual impairment of kidney function. IgAN is one of the common primary glomerulopathies in adults and a common cause of kidney disease in children. Through its unique mechanism of action, sparsentane can effectively regulate the endothelin and angiotensin II systems, reduce glomerular inflammation and fibrosis, thereby improving patients' renal function.

The pharmacological effects of sparsentane involve two key signaling pathways. First, as an endothelin receptor antagonist, it can inhibit the activity of endothelinETa receptor, a powerful substance that promotes vasoconstriction and triggers inflammatory responses. In patients with IgAN, endothelin activity is often excessively increased, leading to vasoconstriction and damage to kidney tissue. Secondly, as an angiotensin II receptor antagonist (ARB), sparsentane reduces the contraction of renal blood vessels by blocking the action of angiotensin II, further reducing the burden on the kidneys. Through these two mechanisms, sparsentane can effectively slow down the progression of kidney disease, protect kidney function, reduce urinary protein excretion, and delay the occurrence of kidney damage.

In addition to its use inIgAN, sparsentan is also being studied in focal segmental glomerulosclerosis (FSGS). FSGS is a kidney disease caused by partial sclerosis of the renal tubules and glomeruli, often leading to severe renal failure. Because sparsentane can alleviate inflammation and fibrosis in the kidney by regulating angiotensin II and the endothelin system, it is considered to have the potential to become an effective drug for the treatment of FSGS. Although clinical trials for FSGS are still ongoing, early findings suggest that sparsentane may be effective in slowing disease progression in these patients.

Reference materials:https://www.sparsentan.com/